A phase I/II trial of gemcitabine (Gemzar) plus ABI-007 (ABRAXANE) in patients with advanced metastatic pancreatic cancer
Phase of Trial: Phase I/II
Latest Information Update: 02 Dec 2016
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 02 Dec 2016 Results (n=37) of PET response and survival analysis presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- 04 Oct 2011 Status changed from active, no longer recruiting to completed.
- 04 Oct 2011 Results were published in the online version of the Journal of Clinical Oncology.